Advertisement

Midterm and Long-Term Impacts of GnRH Agonists Treatments

  • C. Chao
  • S. Christin-Maitre

Abstract

GnRH analogs treatment is effective on final height, especially when treatment is started before the age of 6 years old.On average, the BMI of girls with precocious puberty treated with GnRH analogs is higher than the BMI of girls from the general population. However, large variability is reported in the literature.GnRH analogs treatment does not seem to alter final postpubertal bone maturation.GnRH analogs treatment does not seem to alter fertility of men and women treated during their infancy.Few data have been reported concerning psychological evaluations of children treated during their infancy by GnRH analog treatment for precocious puberty.

Keywords

Bone Mineral Density Final Height Adult Height Precocious Puberty GnRH Analog 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Poomthavorn P (2011) Adult height, body mass index and time of menarche of girls with idiopathic central precocious puberty after gonadotropin-releasing hormone analogue treatment. Gynecol Endocrinol 27:524–528CrossRefPubMedGoogle Scholar
  2. 2.
    Heger S, Partsch CJ, Sippell WG (1999) Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function. J Clin Endocrinol Metab 84:4583–4590PubMedGoogle Scholar
  3. 3.
    Lazar L, Padoa A, Phillip M (2007) Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity. J Clin Endocrinol Metab 92:3483–3489CrossRefPubMedGoogle Scholar
  4. 4.
    Pasquino A, Pucarelli I, Accardo F et al (2008) Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function. J Clin Endocrinol Metab 93:190–195CrossRefPubMedGoogle Scholar
  5. 5.
    Baek J-W, Nam H-K, Jin D, oh YJ, Rhie Y-J, Lee K-H (2014) Age of menarche and near adult height after long-term gonadotropin-releasing hormone agonist treatment in girls with central precocious puberty. Ann Pediatr Endocrinol Metab 9:27–31CrossRefGoogle Scholar
  6. 6.
    Magiakou M, Manousaki D (2010) The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study. J Clin Endocrinol Metab 95:109–117CrossRefPubMedGoogle Scholar
  7. 7.
    Tanaka T, Niimi H, Matsuo N (2005) Leuprorelin acetate: evaluation of effectiveness of treatment and recovery of gonadal function. The TAP-144-SR Japanese Study group on central precocious puberty. J Clin Endocrinol Metab 90:1371–1376CrossRefPubMedGoogle Scholar
  8. 8.
    Paterson WF, McNeill E, Young D, Donaldson MD (2004) Auxological outcome and time to menarche following long-acting goserelin therapy in girls with central precocious or early puberty. Clin Endocrinol 61:626–634CrossRefGoogle Scholar
  9. 9.
    Carel J, Roger M, Ispas S (1999) Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. J Clin Endocrinol Metab 84:1973–1978CrossRefPubMedGoogle Scholar
  10. 10.
    Fuqua JS (2013) Treatment and outcomes of precocious puberty: an update. J Clin Endocrinol Metab 98:1–11CrossRefGoogle Scholar
  11. 11.
    Bertelloni S, Mul D (2008) Treatment of central precocious puberty by GnRH analogs: long term outcome in men. Asian J Androl 10:525–534CrossRefPubMedGoogle Scholar
  12. 12.
    Klein K, Barnes K, Jones J (2001) Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience. J Clin Endocrinol Metab 86:4711–4716CrossRefPubMedGoogle Scholar
  13. 13.
    Feuillan PP, Jones JV, Barnes K et al (1999) Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty. J Clin Endocrinol Metab 84:44–49CrossRefPubMedGoogle Scholar
  14. 14.
    Chiocca E, Dati E, Baroncelli GI et al (2009) Body mass index and body composition in adolescents treated with gonadotropin-releasing hormone analogue triptorelin depot for central precocious puberty: data at near final height. Neuroendocrinology 89:441–447CrossRefPubMedGoogle Scholar
  15. 15.
    van der Sluis IM, Boot AM, Hop WC et al (2002) Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy. J Clin Endocrinol Metab 87:506–512CrossRefPubMedGoogle Scholar
  16. 16.
    Lee SJ, Yang EM, Seo JY, Kim CJ (2012) Effects of gonadotropin-releasing hormone agonist therapy on body mass index and height in girls with central precocious puberty. Chonnam Med J 48:27–31PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Traggiai C, Perucchin PP, Zerbini K et al (2005) Outcome after depot gonadotrophin-releasing hormone agonist treatment for central precocious puberty: effects on body mass index and final height. Eur J Endocrinol 153:463–464CrossRefPubMedGoogle Scholar
  18. 18.
    Arrigo T, De Luca F, Antoniazzi F et al (2004) Reduction of baseline body mass index under gonadotropin-suppressive therapy in girls with idiopathic precocious puberty. Eur J Endocrinol 150:533–537CrossRefPubMedGoogle Scholar
  19. 19.
    Palmert MR, Mansfield MJ, Crowley WF et al (1999) Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty. J Clin Endocrinol Metab 84:4480–4488PubMedGoogle Scholar
  20. 20.
    Feuillan PP, Jones JV, Barnes KM et al (2000) Boys with precocious puberty due to hypothalamic hamartoma: reproductive axis after discontinuation of gonadotropin-releasing hormone analog therapy. J Clin Endocrinol Metab 85:4036–4038CrossRefPubMedGoogle Scholar
  21. 21.
    Rotterdam ESHRE/ASRM sponsored PCOS consensus workshop group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41–47CrossRefGoogle Scholar
  22. 22.
    Carel JC, Eugster EA, Rogol A et al (2009) Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 123:752–762CrossRefGoogle Scholar
  23. 23.
    Franceschi R, Gaudino R, Marcolongo A (2010) Prevalence of polycystic ovary syndrome in young women who had idiopathic central precocious puberty. Fertil Steril 93:1185–1191CrossRefPubMedGoogle Scholar
  24. 24.
    Chiavaroli V, Liberati M, D’Antonio F et al (2010) GnRH analog therapy in girls with early puberty is associated with the achievement of predicted final height but also with increased risk of polycystic ovary syndrome. Eur J Endocrinol 163:55–62CrossRefPubMedGoogle Scholar
  25. 25.
    Lazar L, Meyerovitch J, de Vries L, Phillip M, Lebenthal Y (2014) Treated and untreated women with idiopathic precocious puberty: long term follow-up and reproductive outcome between the third and fifth decades. Clin Endocrinol 80:570–576CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • C. Chao
    • 1
  • S. Christin-Maitre
    • 1
  1. 1.Reproductive Endocrine UnitHôpital Saint-Antoine, AP-HP, Faculté Pierre et Marie CurieParisFrance

Personalised recommendations